Parkev Tatevosian, CFA on $LLY

Channel profile →Sources cited by the channel: Barclays analyst Dan Levy, Meta management and CEO Mark Zuckerberg, Nike management3 entries

Parkev Tatevosian, CFA has discussed $LLY in 3 videos since 2026-09-26. The latest, on 2026-11-10, was bullish.

2026-11-10Bullish
“My Forever Portfolio: 4 Spectacular Stocks You Can Buy Now and Never Sell”
AI summary · Eli Lilly is a buy-and-hold-forever recommendation because its decades of serial successes, not just weight-loss treatments, make the current success non-fleeting; with the stock at $1,366 versus his $1,662 valuation, he owns shares and wants to add more.

What you see here is my valuation, and my discounted cash flow model for the first stock I'm going to mention that you can buy now and hold forever, which is Eli Lilly.

Eli Lilly is a pharmaceutical company with decades of experience in researching and developing treatments that generate billions of dollars in sales and profits. Currently, the company is benefiting from its recent success in weight loss treatments, but the company has a history of one success after another.

2026-09-28Bullish
“3 Undervalued Healthcare Stocks Invstors Can Buy Right Now”
AI summary · LLY is undervalued (fair value $1,494 vs price $1,153) due to strong weight-loss drug momentum and FCF growth; expected to rise ~30% in 12-18 months.

We will move from a company with a market value of about one billion dollars to a company with a market value of more than one trillion dollars, which is Eli Lilly. I don't need to explain what Eli Lilly benefits from; the positive momentum is of course the weight loss treatments that have created a sales boom, which reminds me of the sales boom of artificial intelligence companies like Nvidia and Micron.

2026-09-26Bullish
Eli Lilly Might Be the Next Stock I Buy | LLY Stock Analysis
Subscribe or start a trial to unlock this step
1 earlier entry need a subscription
The latest 2 are free to read. Earlier entries keep their date and direction; the text unlocks with a subscription.
Subscribe to read all 1 earlier take